HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI) and is referred to as an IMI project.
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
The Initiative does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is a partnership between the European Union(represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). IMI is the world's biggest public-private partnership (PPP) in the life sciences. EFPIA companies and Associated Partners do not receive any EU funding, but contribute to the projects ‘in kind’, for example by contributing their researchers’ time or providing access to research facilities or resources.